FMR1 and fragile X syndrome: In an early study using 5-azaC in FXS-iPSCs and FXS-iPSC-derived neurons, 5-azaC treatment reactivated FMR1 expression to about 15% to 45% of wildtypes (WTs) in FXS-iPSCs [64].